SIMCERE PHARMACEUTICAL GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.16 HKD | -0.81% |
|
+6.39% | -8.47% |
| Jun. 03 | Simcere Pharmaceutical’s Cancer Drug Shows Positive Results | MT |
| Jun. 03 | Simcere Pharma Presents Results of Phase 3 Trial for Anti-Cancer Injection at US Oncology Society Meeting | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,011 | 3,031 | 3,958 | 2,255 | 2,026 | - | - |
| Enterprise Value (EV) 2 | 3,016 | 2,945 | 3,796 | 2,173 | 1,746 | 1,660 | 1,585 |
| P/E ratio | 26.9 x | 12.6 x | 28.5 x | 22.7 x | 14.8 x | 11.6 x | 10 x |
| Yield | 1.99% | 2.05% | 1.56% | 2.62% | 2.36% | 2.94% | 3.31% |
| Capitalization / Revenue | 4.37 x | 3.86 x | 4.3 x | 2.46 x | 1.96 x | 1.69 x | 1.48 x |
| EV / Revenue | 4.38 x | 3.75 x | 4.13 x | 2.37 x | 1.69 x | 1.38 x | 1.16 x |
| EV / EBITDA | 27.9 x | 11 x | 24 x | 16.6 x | 9.23 x | 7.05 x | 5.64 x |
| EV / FCF | - | -46.9 x | - | - | 16.8 x | 15.9 x | 12.6 x |
| FCF Yield | - | -2.13% | - | - | 5.94% | 6.29% | 7.95% |
| Price to Book | 3.4 x | 2.97 x | 3.83 x | 2.21 x | 1.91 x | 1.71 x | 1.5 x |
| Nbr of stocks (in thousands) | 2,608,642 | 2,628,291 | 2,660,377 | 2,616,723 | 2,549,355 | - | - |
| Reference price 3 | 7.533 | 7.325 | 10.26 | 6.117 | 5.755 | 5.755 | 5.755 |
| Announcement Date | 3/25/21 | 3/24/22 | 3/31/23 | 3/20/24 | - | - | - |
1CNY in Million2USD in Million3CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 746.6 | 688.7 | 785.2 | 919.9 | 917.9 | 1,033 | 1,200 | 1,372 |
| EBITDA 1 | - | 108 | 267 | 158.1 | 131.1 | 189.3 | 235.2 | 281.1 |
| EBIT 1 | - | 74.08 | 178.1 | 125.6 | 98.87 | 139.9 | 188.1 | 237.2 |
| Operating Margin | - | 10.76% | 22.68% | 13.65% | 10.77% | 13.55% | 15.68% | 17.29% |
| Earnings before Tax (EBT) 1 | - | 123 | 220.1 | 129.3 | 102.8 | 143.5 | 192.5 | 244.4 |
| Net income 1 | 148.8 | 102.3 | 236.7 | 135.8 | 99.28 | 140.5 | 179.8 | 208.6 |
| Net margin | 19.93% | 14.85% | 30.14% | 14.76% | 10.82% | 13.61% | 14.98% | 15.21% |
| EPS 2 | - | 0.2800 | 0.5800 | 0.3600 | 0.2700 | 0.3888 | 0.4976 | 0.5756 |
| Free Cash Flow 1 | - | - | -62.76 | - | - | 103.7 | 104.5 | 126 |
| FCF margin | - | - | -7.99% | - | - | 10.04% | 8.7% | 9.19% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 54.8% | 44.41% | 44.84% |
| FCF Conversion (Net income) | - | - | - | - | - | 73.82% | 58.12% | 60.41% |
| Dividend per Share 2 | - | 0.1500 | 0.1500 | 0.1600 | 0.1600 | 0.1359 | 0.1690 | 0.1905 |
| Announcement Date | 10/12/20 | 3/25/21 | 3/24/22 | 3/31/23 | 3/20/24 | - | - | - |
1USD in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 |
|---|---|---|
| Net sales 1 | - | 448.4 |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income | 312.5 | - |
| Net margin | - | - |
| EPS | 0.8600 | - |
| Dividend per Share | - | - |
| Announcement Date | 8/21/23 | 3/20/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 4.55 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 86 | 162 | 81.8 | 280 | 367 | 441 |
| Leverage (Debt/EBITDA) | - | 0.0421 x | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -62.8 | - | - | 104 | 104 | 126 |
| ROE (net income / shareholders' equity) | - | 19.7% | 25.7% | 13.8% | 9.96% | 12.4% | 14.7% | 15.8% |
| ROA (Net income/ Total Assets) | - | 7.56% | 14.3% | 8.91% | 6.61% | 8.39% | 10.1% | 11.1% |
| Assets 1 | - | 1,353 | 1,657 | 1,524 | 1,503 | 1,676 | 1,783 | 1,876 |
| Book Value Per Share 2 | - | 2.220 | 2.470 | 2.680 | 2.770 | 3.010 | 3.370 | 3.830 |
| Cash Flow per Share 2 | - | 0.0400 | -0.0800 | 0.5200 | - | 0.2400 | 0.3900 | - |
| Capex 1 | - | 54.4 | 32 | 49.9 | - | 84.7 | 82.5 | 89 |
| Capex / Sales | - | 7.9% | 4.07% | 5.43% | - | 8.2% | 6.87% | 6.48% |
| Announcement Date | 10/12/20 | 3/25/21 | 3/24/22 | 3/31/23 | 3/20/24 | - | - | - |
1USD in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.755
CNY
Average target price
7.984
CNY
Spread / Average Target
+38.74%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.62% | 2.03B | |
| +16.99% | 41.07B | |
| +24.37% | 22.65B | |
| +19.96% | 14.14B | |
| +52.02% | 12.09B | |
| -0.05% | 6.79B | |
| -10.79% | 6.91B | |
| -8.87% | 5.73B | |
| +15.28% | 5.59B | |
| +4.00% | 4.82B |
- Stock Market
- Equities
- 2096 Stock
- Financials Simcere Pharmaceutical Group Limited
